- Home
- HBB vs CERT Comparison
HBB vs CERT Comparison
Compare HBB & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HBB | CERT |
|---|---|---|
| Founded | 1904 | 2008 |
| Country | United States | United States |
| Employees | N/A | 1546 |
| Industry | Home Furnishings | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.8M | 1.4B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HBB | CERT |
|---|---|---|
| Price | $16.53 | $8.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $13.88 |
| AVG Volume (30 Days) | 21.5K | ★ 2.0M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | ★ 24.53 | N/A |
| EPS | ★ 2.34 | 0.07 |
| Revenue | ★ $607,430,000.00 | $415,551,000.00 |
| Revenue This Year | N/A | $10.82 |
| Revenue Next Year | N/A | $6.77 |
| P/E Ratio | ★ $7.04 | $126.84 |
| Revenue Growth | N/A | ★ 11.47 |
| 52 Week Low | $12.72 | $8.03 |
| 52 Week High | $21.20 | $15.69 |
Technical Indicators
Market Signals| Indicator | HBB | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 58.33 | 38.45 |
| Support Level | $15.24 | $8.95 |
| Resistance Level | $17.06 | $9.42 |
| Average True Range (ATR) | 0.71 | 0.39 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 60.16 | 14.87 |
Price Performance
Historical ComparisonAbout HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.